Novabridge Biosciences (NBP)
NASDAQ:NBP
Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$2.70
--
Market closed
$2.70
--
Day’s Range― - ―
52-Week Range$1.50 - $6.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.03M
Market Cap
$176.53M
Enterprise Value$182.42M
Total Cash (Recent Filing)$30.14M
Total Debt (Recent Filing)$438.46K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Sep 01, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume578,421
30 Day Avg. Volume1,030,700
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.78
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthConsistently low debt-to-equity (roughly 1%–8% historically and ~1% in 2025) reduces solvency risk and preserves strategic optionality. This durable financial flexibility supports continuing R&D and potential partnering or M&A without immediate liquidity stress, lengthening the firm's strategic runway.
Material Cash RunwayA year-end cash balance of ~$210.8M and management's guidance to fund operations through 2028 provide a multi-year runway to advance registrational and Phase 2/3 programs. That reduces near-term dilution risk and allows the company to execute pivotal trials and commercialization planning over a multi-year horizon.
Regulatory Progress For Lead Oncology AssetFDA feedback indicating accelerated-approval eligibility for givastomig based on strong Phase 1b data materially de-risks the timeline to market. A credible regulatory path can shorten commercial lead time, concentrate development resources, and enhance partner interest and eventual uptake if later-phase results confirm early efficacy.
Bears Say
Persistent Negative Cash GenerationMulti-year negative operating and free cash flow since 2021 indicates structural cash burn despite some 2025 improvement. Enduring negative cash generation increases reliance on financing or partnerships over time, heightening dilution risk if clinical programs require larger or prolonged investment to reach commercialization.
Weak Revenue And Recurring LossesRevenue volatility culminating in near-zero receipts in 2024–2025, combined with recurring negative EBIT/EBITDA since 2021, shows the business has yet to establish a consistent commercial foundation. Continued losses erode equity and constrain reinvestment capacity absent successful trial outcomes or new revenue streams.
Pipeline Concentration And Clinical RiskBusiness value is concentrated in two mid-stage assets (givastomig and VIS-101). While promising, this creates high binary risk: adverse Phase 3 or regulatory outcomes for one or both programs would sharply impair growth prospects and commercial viability, making long-term fundamentals contingent on trial success.
NovaBridge Biosciences News
NBP FAQ
What was Novabridge Biosciences’s price range in the past 12 months?
Novabridge Biosciences lowest stock price was $1.50 and its highest was $6.79 in the past 12 months.
What is Novabridge Biosciences’s market cap?
Novabridge Biosciences’s market cap is $176.53M.
When is Novabridge Biosciences’s upcoming earnings report date?
Novabridge Biosciences’s upcoming earnings report date is Sep 01, 2026 which is in 82 days.
How were Novabridge Biosciences’s earnings last quarter?
Currently, no data Available
Is Novabridge Biosciences overvalued?
According to Wall Street analysts Novabridge Biosciences’s price is currently Undervalued.
Does Novabridge Biosciences pay dividends?
Novabridge Biosciences does not currently pay dividends.
What is Novabridge Biosciences’s EPS estimate?
Novabridge Biosciences’s EPS estimate is -0.12.
How many shares outstanding does Novabridge Biosciences have?
Novabridge Biosciences has 115,381,690 shares outstanding.
What happened to Novabridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (233.33% Upside)
$9.00 (233.33% Upside)
Blogger Sentiment
Bullish
NBP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 350.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $520.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Company Description
Novabridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(233.33% Upside)
Ownership Overview
0.48% Insiders
0.07% Mutual Funds
13.39% Other Institutional Investors
85.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---